Klusa Vija
Department of Pharmacology, Faculty of Medicine, University of Latvia, Jelgavas iela 1, Riga, Latvia.
Pharmacol Res. 2016 Nov;113(Pt B):754-759. doi: 10.1016/j.phrs.2016.05.017. Epub 2016 May 24.
This mini review is devoted to the design and pharmacological studies of novel atypical 1,4-dihydropyridine (DHP) derivatives which differ to a great extent from the traditional DHPs either by lack of neuronal calcium channel blocking activity and/or inability to protect mitochondrial processes. About 100 new DHP derivatives were screened and the mostly active were selected for detailed studies. The compounds of the series of the amino acid ("free" plus "crypto")-containing DHPs and lipophilic di-cyclic DHPs demonstrated long-lasting neuroprotective and/or memory-enhancing action, particularly at low doses (0.005-0.05mg/kg) in different neurodeficiency rat or mice models, and exerted neurotransmitter-modulating effects. The studies have shown an ability of these atypical DHPs to normalize the expression of neuronal proteins, which participate in the regulation of neurotransmission (particularly of the GABAergic system) and synaptic plasticity that has been impaired in animal models, including Alzheimer's disease transgenic mice. The obtained results indicate that the tested DHP compounds can be considered as candidate molecules either for their further chemical modifications or for the more detailed studies to identify cell targets essential for neuroprotection and memory enhancing.
本综述致力于新型非典型1,4 - 二氢吡啶(DHP)衍生物的设计和药理学研究,这些衍生物在很大程度上不同于传统的二氢吡啶,其区别在于缺乏神经元钙通道阻断活性和/或无法保护线粒体过程。筛选了约100种新的二氢吡啶衍生物,并选择了活性最强的进行详细研究。含氨基酸(“游离”加“隐秘”)的二氢吡啶系列化合物和亲脂性双环二氢吡啶在不同的神经缺陷大鼠或小鼠模型中,尤其在低剂量(0.005 - 0.05mg/kg)时,表现出持久的神经保护和/或记忆增强作用,并发挥神经递质调节作用。研究表明,这些非典型二氢吡啶能够使神经元蛋白的表达正常化,这些蛋白参与神经传递(特别是GABA能系统)的调节以及在动物模型(包括阿尔茨海默病转基因小鼠)中受损的突触可塑性。所得结果表明,所测试的二氢吡啶化合物可被视为进一步化学修饰或进行更详细研究以确定神经保护和记忆增强所必需的细胞靶点的候选分子。